Diabetes Care Devices Market Outlook: Advanced Monitoring Solutions and Growth Opportunities

According to IMARC Group's latest research publication, the global diabetes care devices market size was valued at USD 36.5 Billion in 2025. Looking forward, the market is projected to reach USD 64.5 Billion by 2034, exhibiting a CAGR of 6.35% during 2026–2034.

The diabetes care devices market represents a critical segment within global healthcare systems, supported by the rising prevalence of diabetes, increasing adoption of digital health technologies, and continuous innovation in monitoring and treatment solutions. Growing awareness around disease management and the need for real-time glucose tracking are further contributing to market expansion..

Diabetes Care Devices Market Drivers

• Increasing Prevalence of Diabetes: The growing incidence of diabetes, driven by sedentary lifestyles, urbanization, aging populations, and dietary patterns, is a primary factor supporting market growth. The rising number of diagnosed patients is increasing demand for monitoring devices, insulin delivery systems, and digital management tools.
• Technological Advancements and Innovation: Continuous innovation is improving device accuracy, usability, and patient outcomes. In March 2024, Roche introduced the Accu-Chek SmartGuide CGM system, designed to provide real-time monitoring with predictive alerts and improved accuracy metrics. Such developments are enhancing clinical effectiveness and patient convenience.
• Expansion of Retail and Online Distribution: The increasing availability of diabetes care devices through retail pharmacies, online platforms, and direct-to-consumer channels is improving accessibility. This shift allows first-time users to adopt monitoring solutions more easily, particularly in regions with expanding middle-class populations and rising healthcare awareness.

Explore Updated 2026 Market Trends & Analysis

Diabetes Care Devices Industry Overview

The expansion of private health insurance and rising disposable incomes in developing economies are enabling broader access to diabetes care devices. Insurance coverage plays a key role in supporting long-term adoption and regular usage of monitoring systems.Diabetes Care Devices Market Trends

The adoption of connected devices and digital ecosystems is enabling seamless data tracking and sharing between patients and healthcare providers. This trend is supporting proactive disease management and personalized treatment approaches.

Continuous glucose monitoring devices are gaining traction due to their ability to provide real-time insights and reduce dependence on traditional fingerstick methods. Improvements in sensor technology and user-friendly interfaces are supporting wider adoption.

The introduction of over-the-counter glucose monitoring devices is expanding access to diabetes management tools. These solutions reduce dependency on prescriptions and encourage early monitoring among individuals at risk.

Competitive Landscape

The global diabetes care devices market includes several established players focusing on product innovation, strategic collaborations, and geographic expansion.

Key companies include:

• Abbott Laboratories
• ACON Laboratories Inc.
• Ascensia Diabetes Care Holdings AG
• Becton Dickinson and Company
• Bionime Corporation
• Dexcom Inc.
• F. Hoffmann-La Roche AG
• Johnson and Johnson
• Medtronic plc
• Novo Nordisk A/S
• Sinocare Inc.
• Terumo Corporation

Market Segmentation

By Type

• Blood Glucose Monitoring Devices
• Continuous Glucose Monitoring Devices
• Insulin Delivery Devices (Pumps, Pens, Syringes, Jet Injectors)

Blood glucose monitoring devices lead the segment due to affordability and ease of use.

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Diabetes Clinics/Centers
• Online Pharmacies

Hospital pharmacies dominate due to strong patient trust and integrated care services.

By End User

• Hospitals
• Homecare
• Diagnostic Centers
• Ambulatory Surgery Centers

Hospitals remain the largest end-user segment, supported by infrastructure and patient volume.

Regional Insights

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the largest market share, accounting for over 38.6%, supported by advanced healthcare infrastructure, high awareness levels, and strong presence of leading manufacturers.

Recent Developments

• September 2024: The FDA approved the Eversense 365 CGM system, offering extended sensor life and improved patient convenience.
• August 2024: Abbott and Medtronic announced collaboration to integrate glucose monitoring with insulin delivery systems.
• August 2024: Medtronic received authorization for Simplera, a disposable all-in-one CGM device.
• March 2024: Roche introduced the Accu-Chek SmartGuide CGM with predictive alerts and improved accuracy.
• March 2024: Dexcom received approval for Stelo, an over-the-counter glucose biosensor designed for adults with Type 2 diabetes.

Note

Additional insights, data points, or customized analysis can be incorporated based on specific research or business requirements.